Global Pediatric Growth Hormone Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pediatric Growth Hormone Market Insights, Forecast to 2034
Growth hormones deficiency is a rare condition but it mainly affects the children. The recombinant form of a growth hormone called somatotropin is generally prescribed to treat pediatric patients with growth hormone deficiency. Somatotropin or growth hormone injections are prescribed for pediatric patients with turner syndrome, short stature, Prader-Willi syndrome, Noonan syndrome and other disorders.
Market Analysis and InsightsGlobal Pediatric Growth Hormone Market
Global Pediatric Growth Hormone market is expected to reach to US$ 3460 million in 2024, with a positive growth of %, compared with US$ 3300 million in 2022. Backed with the increasing demand from downstream industries, Pediatric Growth Hormone industry is evaluated to reach US$ 4690 million in 2029. The CAGR will be 5.2% during 2024 to 2029.
The global pediatric growth hormone market refers to the market for medications and therapies used to treat growth hormone deficiency (GHD) and related disorders in children. Growth hormone is an important hormone produced by the pituitary gland that plays a crucial role in regulating growth, development, and metabolism.
Pediatric growth hormone deficiency can occur due to various factors, including genetic conditions, congenital anomalies, brain injuries, and certain medical treatments. Treatment with growth hormone therapy aims to stimulate growth and development in children who have insufficient or inadequate production of growth hormone.
The global market for pediatric growth hormone is primarily driven by factors such as the increasing prevalence of growth hormone deficiency, rising awareness about the benefits of growth hormone therapy, advances in treatment options, and improving healthcare infrastructure.
Growth hormone therapy for children with growth hormone deficiency involves the subcutaneous administration of synthetic growth hormone on a daily basis. The therapy is typically initiated during childhood and continued until the patient reaches adult height or the maximum growth potential is achieved.
Geographically, North America and Europe hold a significant share in the global pediatric growth hormone market due to the well-established healthcare systems, high awareness levels, and the presence of key market players. The Asia Pacific region is also expected to witness significant growth due to the increasing prevalence of growth hormone deficiency and improving healthcare infrastructure.
Key pharmaceutical companies involved in the production and distribution of pediatric growth hormone products include Novo Nordisk, Pfizer, Eli Lilly and Company, Merck & Co., and Ferring Pharmaceuticals, among others. These companies are focused on developing advanced growth hormone formulations, conducting clinical trials, and expanding their product portfolios to address the specific needs of pediatric patients.
It’s important to note that the pediatric growth hormone market is regulated, and treatment decisions are made based on the diagnosis and guidance of healthcare professionals specializing in pediatric endocrinology. Proper assessment, diagnosis, and monitoring of the child’s growth and hormone levels are essential for safe and effective treatment.
In summary, the global pediatric growth hormone market is driven by factors such as the increasing prevalence of growth hormone deficiency, advances in treatment options, and improving healthcare infrastructure. The market is expected to witness steady growth as awareness about growth hormone therapy increases and healthcare providers continue to diagnose and treat pediatric patients with growth hormone deficiency.
Report Covers
This report presents an overview of global Pediatric Growth Hormone market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pediatric Growth Hormone market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Merck KGaA
Novo Nordisk A/S
Ferring B.V
Genentech, Inc.
Pfizer Inc.
Eli Lilly & Company
Novartis AG
BioPartners GmbH
Ipsen Biopharmaceuticals
Teva Pharmaceuticals
Anhui Anke Biotechnology (Group) Co., Ltd.
LG Chem
GeneScience Pharmaceuticals Co., Ltd.
Ascendis Pharma A/S
Changchun High & New Tech Industry Inc
Segment by Type
Growth Hormone Deficiency
Turner Syndrome
Prader-Willi Syndrome
Noonan Syndrome
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Pediatric Growth Hormone introduction, etc. Pediatric Growth Hormone Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Pediatric Growth Hormone
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Pediatric Growth Hormone Market
Global Pediatric Growth Hormone market is expected to reach to US$ 3460 million in 2024, with a positive growth of %, compared with US$ 3300 million in 2022. Backed with the increasing demand from downstream industries, Pediatric Growth Hormone industry is evaluated to reach US$ 4690 million in 2029. The CAGR will be 5.2% during 2024 to 2029.
The global pediatric growth hormone market refers to the market for medications and therapies used to treat growth hormone deficiency (GHD) and related disorders in children. Growth hormone is an important hormone produced by the pituitary gland that plays a crucial role in regulating growth, development, and metabolism.
Pediatric growth hormone deficiency can occur due to various factors, including genetic conditions, congenital anomalies, brain injuries, and certain medical treatments. Treatment with growth hormone therapy aims to stimulate growth and development in children who have insufficient or inadequate production of growth hormone.
The global market for pediatric growth hormone is primarily driven by factors such as the increasing prevalence of growth hormone deficiency, rising awareness about the benefits of growth hormone therapy, advances in treatment options, and improving healthcare infrastructure.
Growth hormone therapy for children with growth hormone deficiency involves the subcutaneous administration of synthetic growth hormone on a daily basis. The therapy is typically initiated during childhood and continued until the patient reaches adult height or the maximum growth potential is achieved.
Geographically, North America and Europe hold a significant share in the global pediatric growth hormone market due to the well-established healthcare systems, high awareness levels, and the presence of key market players. The Asia Pacific region is also expected to witness significant growth due to the increasing prevalence of growth hormone deficiency and improving healthcare infrastructure.
Key pharmaceutical companies involved in the production and distribution of pediatric growth hormone products include Novo Nordisk, Pfizer, Eli Lilly and Company, Merck & Co., and Ferring Pharmaceuticals, among others. These companies are focused on developing advanced growth hormone formulations, conducting clinical trials, and expanding their product portfolios to address the specific needs of pediatric patients.
It’s important to note that the pediatric growth hormone market is regulated, and treatment decisions are made based on the diagnosis and guidance of healthcare professionals specializing in pediatric endocrinology. Proper assessment, diagnosis, and monitoring of the child’s growth and hormone levels are essential for safe and effective treatment.
In summary, the global pediatric growth hormone market is driven by factors such as the increasing prevalence of growth hormone deficiency, advances in treatment options, and improving healthcare infrastructure. The market is expected to witness steady growth as awareness about growth hormone therapy increases and healthcare providers continue to diagnose and treat pediatric patients with growth hormone deficiency.
Report Covers
This report presents an overview of global Pediatric Growth Hormone market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pediatric Growth Hormone market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Merck KGaA
Novo Nordisk A/S
Ferring B.V
Genentech, Inc.
Pfizer Inc.
Eli Lilly & Company
Novartis AG
BioPartners GmbH
Ipsen Biopharmaceuticals
Teva Pharmaceuticals
Anhui Anke Biotechnology (Group) Co., Ltd.
LG Chem
GeneScience Pharmaceuticals Co., Ltd.
Ascendis Pharma A/S
Changchun High & New Tech Industry Inc
Segment by Type
Growth Hormone Deficiency
Turner Syndrome
Prader-Willi Syndrome
Noonan Syndrome
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Pediatric Growth Hormone introduction, etc. Pediatric Growth Hormone Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Pediatric Growth Hormone
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices